Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of NewAmsterdam Pharma Company NV (NASDAQ: NAMS) was $22.43 for the day, down -1.54% from the previous closing price of $22.78. In other words, the price has decreased by -$1.54 from its previous closing price. On the day, 1.17 million shares were traded. NAMS stock price reached its highest trading level at $23.59 during the session, while it also had its lowest trading level at $21.55.
Ratios:
Our analysis of NAMS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 19.98 and its Current Ratio is at 19.98. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on July 17, 2025, initiated with a Neutral rating and assigned the stock a target price of $27.
On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $42.
On June 10, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $44.Stifel initiated its Buy rating on June 10, 2025, with a $44 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 16 ’25 when Kling Douglas F sold 51,043 shares for $21.10 per share. The transaction valued at 1,077,007 led to the insider holds 44,000 shares of the business.
Kling Douglas F sold 47,569 shares of NAMS for $1,019,648 on Jul 15 ’25. The Chief Operating Officer now owns 44,000 shares after completing the transaction at $21.44 per share. On Jul 14 ’25, another insider, NAP PoolCo B.V., who serves as the Affiliate of the company, bought 1,433,193 shares for $21.56 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NAMS now has a Market Capitalization of 2518238464 and an Enterprise Value of 1710143232. For the stock, the TTM Price-to-Sale (P/S) ratio is 53.42 while its Price-to-Book (P/B) ratio in mrq is 3.24. Its current Enterprise Value per Revenue stands at 36.278 whereas that against EBITDA is -9.021.
Stock Price History:
The Beta on a monthly basis for NAMS is 0.00, which has changed by 0.29991305 over the last 52 weeks, in comparison to a change of 0.16821623 over the same period for the S&P500. Over the past 52 weeks, NAMS has reached a high of $27.29, while it has fallen to a 52-week low of $14.06. The 50-Day Moving Average of the stock is 11.84%, while the 200-Day Moving Average is calculated to be 7.96%.
Shares Statistics:
NAMS traded an average of 852.41K shares per day over the past three months and 840830 shares per day over the past ten days. A total of 112.17M shares are outstanding, with a floating share count of 62.20M. Insiders hold about 44.60% of the company’s shares, while institutions hold 57.64% stake in the company. Shares short for NAMS as of 1752537600 were 6878437 with a Short Ratio of 8.07, compared to 1749772800 on 6970274. Therefore, it implies a Short% of Shares Outstanding of 6878437 and a Short% of Float of 7.31.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
